BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 28178623)

  • 1. The TCL1A oncoprotein interacts directly with the NF-kappaB inhibitor IkappaB.
    Ropars V; Despouy G; Stern MH; Benichou S; Roumestand C; Arold ST
    PLoS One; 2009 Aug; 4(8):e6567. PubMed ID: 19668332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular Ligand-Receptor Perturbations Unravel MEIS2 as a Key Factor for the Aggressive Progression and Prognosis in Stage II/III Colorectal Cancer.
    Xu H; Chen S; Li J; Weng S; Ren Y; Zhang Y; Wang L; Liu L; Guo C; Xing Z; Luo P; Cheng Q; Han X; Liu Z
    J Proteome Res; 2024 Feb; 23(2):760-774. PubMed ID: 38153233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking TCL1A to clonal expansions in blood.
    Danovi S
    Nat Genet; 2023 May; 55(5):727. PubMed ID: 37173527
    [No Abstract]   [Full Text] [Related]  

  • 4. Multi-omics profiling identifies C1QA/B
    Zheng F; Zhang W; Yang B; Chen M
    Ann Transl Med; 2022 Nov; 10(22):1249. PubMed ID: 36544679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a 5-Gene-Based Scoring System by WGCNA and LASSO to Predict Prognosis for Rectal Cancer Patients.
    Huang H; Xu S; Chen A; Li F; Wu J; Tu X; Hu K
    Anal Cell Pathol (Amst); 2021; 2021():6697407. PubMed ID: 33833937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear division cycle 80 promotes malignant progression and predicts clinical outcome in colorectal cancer.
    Yan X; Huang L; Liu L; Qin H; Song Z
    Cancer Med; 2018 Feb; 7(2):420-432. PubMed ID: 29341479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Modes of Dysregulation of the Proto-Oncogene T-Cell Leukemia/Lymphoma 1A.
    Stachelscheid J; Jiang Q; Herling M
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TCL1A, B Cell Regulation and Tolerance in Renal Transplantation.
    Brinas F; Danger R; Brouard S
    Cells; 2021 Jun; 10(6):. PubMed ID: 34206047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell leukemia/lymphoma-1A predicts the clinical outcome for patients with stage II/III colorectal cancer.
    Li H; Yan X; Liu L; Huang L; Yin M; Pan C; Zhang P; Qin H
    Biomed Pharmacother; 2017 Apr; 88():924-930. PubMed ID: 28178623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer.
    Matsuyama T; Ishikawa T; Mogushi K; Yoshida T; Iida S; Uetake H; Mizushima H; Tanaka H; Sugihara K
    Int J Cancer; 2010 Nov; 127(10):2292-9. PubMed ID: 20162577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
    Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
    Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.
    Gao J; Li N; Dong Y; Li S; Xu L; Li X; Li Y; Li Z; Ng SS; Sung JJ; Shen L; Yu J
    Oncogene; 2015 Jul; 34(31):4142-52. PubMed ID: 25362853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.